DRG Epidemiology's coverage of Myasthenia Gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Myasthenia Gravis for…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key type 2 diabetes patient populations covering 171 countries and more than…
DRG Epidemiology's coverage of Myasthenia Gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Myasthenia Gravis for…
DRG Epidemiology's coverage of T2D comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of T2D for each…
DRG Epidemiology's coverage of Myasthenia Gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Myasthenia Gravis for…
The drug landscape for major depressive disorder (MDD) consists of numerous safe and effective treatment options, many of which are available as inexpensive generics. Agents for treating MDD span…
Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malignant…
Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence…
Breast cancer is the most commonly diagnosed cancer among Chinese women. A high incidence and a prolonged treatment duration make the treatment of breast cancer a lucrative commercial opportunity…
The approval two CAR T-cell therapies for relapsed / refractory B-cell hematological malignancies—Novatis’ Kymriah for acute lymphoblastic leukemia (ALL) and large B-cell lymphoma and Kite…
DRG Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AMD for…
For decades, the treatment landscape of small-cell lung cancer (SCLC) has been dominated by chemotherapy or chemoradiotherapy. In 2018, BristolMyers Squibb’s Opdivo became the first immune…
Migraine presents a major public health burden in China, leading to impaired quality of life, widespread health loss, and loss of productivity for a sizeable population. Owing to migraine’s…
Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands that may occur alone (primary SS) or with a…
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 520 currently available and novel biosimilar products, detailing…